Skip to main content

Table 1 Baseline clinical and demographic characteristics of RACERS participants

From: Beneficial effects of recombinant CER-001 high-density lipoprotein infusion in sepsis: results from a bench to bedside translational research project

Intervention

SOC group

CER-001 group

p-value

 

n = 5

n = 15

 

Age (years), mean (SD)

59 (10.29)

56.6 (18.63)

0.789

Male gender, n (%)

2 (40%)

4 (26.4%)

0.573

Site of infection/sepsis, n(%)

 Urine

4 (80%)

7 (46.7%)

 

 Intra-abdominal

0

6 (40%)

0.238

 Other

1 (20%)

2 (13.3%)

 

 Septic shock, n (%)

1 (20%)

6 (40%)

0.795

Hospital unit, n(%)

 Intensive care unit

2 (40%)

7 (46.7%)

0.795

 Nephrology

3 (60%)

8 (53.3%)

 

SOFA score, mean (SD)

6.6 (6.07)

6.07 (4.62)

0.830

SAPS II score, mean (SD)

31.8 (11.9)

27.6 (14.2)

0.569

Immunocompromised patients, n (%)

1 (20%)

1 (13.3%)

0.717

Time for enrollment from hospital admission, median (IQR)

0 (0–26)

2  (1-6)

1

Mean arterial pressure (MAP), mean (SD)

85.8 (9.73)

81 (14.22)

0.495

Vasopressors use, n (%)

1 (20%)

6 (40%)

0.573

Vasopressors dose (mcg/kg/min), mean (SD)a

0.2 (0.1)

0.17 (0.1)

0.630

Mechanical ventilation, n(%)

2 (40%)

6 (40%)

1

Acute kidney injury (AKI), n (%)

3 (60%)

8 (53.3%)

0.795

Renal replacement therapy (RRT), n (%)

1 (20%)

2 (13.3%)

0.717

  1. Legend. SD standard deviation, ICU intensive care unit, ARDS acute respiratory distress syndrome, SAPS II Simplified Acute Physiology Score II, SOFA Sequential Organ Failure Assessment
  2. aValues calculated only on ICU patients on vasopressors at treatment start